BioAge Labs, Inc. Common Stock (BIOA)

• Market cap: $152M
• 1 day: 0.71%
• 5 days: 10.44%
• 1 month: -1.17%
• 3 months: -21.23%
• 6 months: -82.42%
• Year to date: -23.92%
• 1 year: -76.90%
• 5 years: -76.90%
• 10 years: -76.90%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Employees: 64

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

23% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 30

12% more funds holding

Funds holding: 57 [Q3] → 64 (+7) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

29% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 5 (-2) [Q4]

74% less capital invested

Capital invested by funds: $430M [Q3] → $114M (-$316M) [Q4]

1146.94% less ownership

Funds ownership: 1201.73% [Q3] → 54.78% (-1146.94%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5 18% upside
• Avg. target: $5 18% upside
• High target: $5 18% upside

2 analyst ratings

• positive: 0 0%
• neutral: 1 50%
• negative: 1 50%

Citigroup Samantha Semenkow 27% 1-year accuracy 3 / 11 met price target	18% upside $5	Neutral Maintained	24 Mar 2025
Morgan Stanley Jeffrey Hung 12% 1-year accuracy 3 / 26 met price target	18% upside $5	Underweight Assumed	7 Mar 2025